AVAV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AVAV is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The business has strong defense-demand catalysts and analysts remain mostly constructive, but the chart is still bearish and recent earnings showed losses with margin pressure. Since the investor is impatient and does not want to wait for a better entry, my direct view is to hold off rather than buy today.
The current trend is weak. AVAV closed at 167.84, essentially near the S1 support level of 169.712 and still below the pivot at 184.358. MACD is negative and expanding, which confirms downside momentum. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, showing the stock is below its longer-term trend. RSI_6 at 31.558 is near oversold but not yet a strong reversal signal. Overall, technicals favor caution rather than an immediate long entry.
Recent news is supportive for the long term. AeroVironment secured a U.S. Army prototype agreement for Switchblade 400, and another U.S. Army contract was announced to integrate Switchblade 400 into modernization efforts. LOCUST also received FAA approval for domestic use and a Department of Defense agreement to advance deployment, which strengthens the defense-tech growth narrative. Analyst sentiment remains mostly positive, with several Buy ratings and high price targets. Congress trading data is also positive, with 1 reported purchase and no sales in the last 90 days.
Gross margin fell sharply to 24.21, indicating weaker profitability. Analysts have also cut price targets after disappointing results, SCAR-related issues, and BlueHalo integration concerns. Technically, the stock remains under pressure and the recent trend model points to short-term weakness.
Latest quarter: 2026/Q3. Revenue rose sharply to 408.0M, up 143.41% YoY, which is a strong growth signal. But profitability was poor: net income was -156.6M and EPS was -3.15, both still negative. Gross margin dropped to 24.21, down 35.78% YoY, showing margin compression. So the company is growing fast, but earnings quality has not yet caught up.
Analyst tone is still mostly bullish, but target changes have been mixed. Clear Street initiated/maintained a Buy with a $293 target, citing revenue inflection and BlueHalo commercialization, and later reiterated Buy after the Army prototype agreement. Jefferies, Stifel, Canaccord, BTIG, and RBC all cut targets after Q3 and SCAR-related disappointment, though most kept Buy or Outperform-equivalent views. UBS is more cautious with a Neutral rating. Overall Wall Street pros see a promising long-term defense growth story, but they also acknowledge execution issues, estimate cuts, and near-term margin uncertainty.
